Filter
87
Filtered Results: 87
Text search:
DNDi
Featured
Recommendations
8
New Publications
12
Language
Document type
Studies & Reports
27
No document type
20
Guidelines
8
Videos
7
Strategic & Response Plan
7
Resource Platforms
5
Manuals
4
Fact sheets
4
Situation Updates
3
Infographics
2
Countries / Regions
Global
12
Latin America and the Carribbean
6
Africa
5
Colombia
3
Ethiopia
3
Kenya
2
West and Central Africa
2
East and Southern Africa
2
Southern Africa
2
Brazil
2
Asia
1
Congo, Democratic Republic of
1
South–East Asia Region
1
North America
1
Uruguay
1
Argentina
1
Bangladesh
1
Uganda
1
Zambia
1
India
1
Authors & Publishers
Publication Years
Category
Studies & Reports
5
Chagas
4
Guidelines
4
Leishmaniasis
4
Statistics
3
Disease Prevention & Control
3
Hepatitis
2
Pediatrics
2
Policies & Guidelines HIV & TB
2
Policies
2
NTDs & Others
2
HIV & STI
2
Pharmacy & Technologies
2
COVID-19
1
Virology
1
Medical Devices & Equipment
1
Drugs & Medical Equipment
1
Parasitology
1
Human African Trypanosomiasis
1
Non-communicable Diseases
1
Toolboxes
Capacity Building & Resources
7
Studies & Reports
6
Strategies & Roadmaps
5
Clinical Aspects & Diagnostics
5
Studies & Reports
5
Studies & Reports
4
Clinical Aspects & Diagnostics
3
Local Action
2
Essential Medicines
2
Capacity Building & Resources
2
Information & Education Material (IEC)
2
Statistics & Facts
2
Overview, Studies & Reports
2
Antiretroviral Treatment ART
2
ART Drug Resistance
1
Agriculture & Veterinary
1
HIV testing & services
1
Clinical Aspects, Treatment & Prevention
1
Treatment & Prevention
1
Clinical Aspects
1
Children & Adolescents
1
Opportunistic Infections
1
Introduction to Global Health
1
Prevention Guidelines
1
Treatment Guidelines HIV
1
Concepts of Global Health
1
Curricula & Core Competencies
1
Children
1
Health Equity & Equality
1
Health Personnel
1
Country specific documents
1
Long COVID/ Post-COVID Syndrome
1
Advocacy & Communication
1
Climate Change General
1
Prices and Patents
1
Chagas
1
Leishmaniasis
1
Capacity Building & Resources
1
Information & Education Material (IEC)
1
Information & Education Material (IEC)
1
NTDs General
1
Vector control
1
Mycetoma, Chromoblastomycosis & other deep mycosis
1
Information & Education Material (IEC)
1
Access to treatment and laboratory
1
Health Financing Toolbox
1
Information & Education Material (IEC)
1
Postexposure Prophylaxis (PEP), Pre-Exposure Prophylaxis (PrEP)
1
Asia and Pacific
1
Human Rights & the Right to Health
1
HIV service delivery
1
AMR
1
Reports & Studies
1
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease. Endemic in 21 Latin American countries, the disease can be transmitted by vector insects called triatomines — also known as “kissing bugs” —, foods or beverages contaminated with th...
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...
Chagas is a parasitic disease that affects over 6 million people in the
world. As the disease typically remains asymptomatic for years, new cases
often go unnoticed and unreported, and most people with the disease
are unaware of their condition. Less than 10% of people affected are
diagnosed and...
At the forefront of DNDi’s efforts to develop new treatments is the need to understand the realities and treatment needs of patients and health care staff in the field. The ultimate goal for human African trypanosomiasis (HAT) is a truly simplified
treatment which can be orally administered, impl...
DNDi’s long-term goal for sleeping sickness, also known as human African trypanosomiasis (HAT), is to develop and register two new drugs that are effective against both Stage 1 and Stage 2 of the disease and both subspecies of the parasite, T.b. gambiense and T.b. rhodesiense. T.b. rhodesiense is ...
DNDi is now striving to make fexinidazole available to the majority of people who have T.b. gambiense sleeping sickness. We are supporting a three-year access and pharmacovigilance study that began in 2020 and have so far carried out in-country training of relevant staff in 250 hospitals and...
La enfermedad de Chagas es parasitaria y afecta a más de 6 millones
de personas en el mundo. Como normalmente es asintomática durante
años, los nuevos casos suelen no detectarse ni reportarse y la mayoría
de las personas con la enfermedad no tiene conciencia de su condición.
Se diagnostica ...
Full Perscribing information on Fexinidazole Tablet for oral use
INDICATIONS AND USAGE
Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in pati...
Leishmaniasis is a complex vector-borne disease involving in its transmission several species of protozoan parasites called Leishmania, a wide variety of animal reservoirs and phlebotomine sandflies vectors. Cutaneous Leishmaniasis (CL) is the most common form of the disease, and its clinical manife...
Mycetoma is a slow-growing bacterial or fungal infection, most often of the foot, that may spread to other parts of the body and can cause severe deformity. It is a debilitating disease that most often affects poor people in rural areas with limited access to health care.
Visceral leishmaniasis, the most severe form of leishmaniasis also known as kala-azar, is a life-threatening disease caused by Leishmania parasites which are transmitted by female sandflies. Visceral leishmaniasis causes fever, weight loss, spleen and liver enlargement, and, if not treated, death. P...
1 billion people are at risk of infection with leishmaniasis, a neglected disease strongly linked to poverty. There’s no single, simple cure: current treatments are complex and need to be adapted to the form of the disease and geographical region.
Accessed on 04.04.2023
The Drugs for Neglected Diseases initiative (DNDi) is an international
non-profit organization that discovers, develops, and delivers safe,
effective, and affordable treatments for the most neglected patients
Accessed on 04.04.2023
Die Initiative Medikamente gegen vernachlässigte Krankheiten (Drugs for Neglected Diseases initiative, DNDi) ist eine internationale gemeinnützige Organisation, die sichere, wirksame und bezahlbare Behandlungen für die am meisten vernachlässigten Patient:innen erforsch...
Accessed on 04.04.2023
La Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi) es una organización
internacional sin fines de lucro que proporciona tratamientos seguros, eficaces y
asequibles para los pacientes más desatendidos, desde el laboratorio hasta su llegada
a las manos de ...
Accessed on 04.04.2023
L’initiative Médicaments contre les Maladies Négligées (DNDi) est une organisation
internationale à but non lucratif spécialisée dans la recherche, le développement et la mise à disposition de traitements sûrs, efficaces et abordables aux patients les plus né...
Accessed on 04.04.2023
A Iniciativa Medicamentos para Doenças Negligenciadas (DNDi) é uma organização
internacional sem fins lucrativos que disponibiliza medicamentos seguros, eficazes
e acessíveis para doenças negligenciadas, desde o laboratório até sua chegada às
mãos das popula...
Website last accessed on 14.04.2023
Health workers Luke (Kenya), Juliana (Colombia), and Shishu (India) share the same hope for their patients with leishmaniasis: simple, oral treatments. For the first time ever, it seems leishmaniasis research is moving from neglect to a sense of hope.
Website last accessed on 22.05.2023
The LEAP platform aims to strengthen clinical research capacity, which is lacking in part due to the remoteness and geographic spread of the patients, most of whom live in the most impoverished regions of Africa.
Diabetes Poster - Does your child show any of these symptoms?
